Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

Trial ID or NCT#

NCT00425945

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.

Official Title

Cardiovascular Effects of Pine Bark Extract

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) < 100 mmHg - Body mass index (BMI) 25.0-34.9 - Triglycerides (TG) < 450 mg/dL - Low Density Lipoprotein (LDL) < 200 mg/dL - Fasting blood glucose (FBG) < 126 mg/dL
Exclusion Criteria:
  1. - DBP > 95 mmHg - LDL > 170 mg/dL - TG > 300 mg/dL - FBG > 110 mg/dL
View All Criteria
Show Less

Investigator(s)

Randall Stafford
Randall Stafford
Professor of Medicine (Stanford Center for Research in Disease Prevention)

Contact us to find out if this trial is right for you.

Contact

Rebbeca Drieling
6507236528

View on ClinicalTrials.gov